• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap® PKB/Akt Inhibitor (Oncology)
        • KRAS Oncogene (Oncology)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
        • SHP2 (Oncology)
        • P53 tumour suppressor protein (Oncology)
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 20122 / Astex Pharmaceuticals to Announce 2012 First Quarter Financial Results...

Astex Pharmaceuticals to Announce 2012 First Quarter Financial Results on April 30, 2012

24 April 2012/in 2012, News

Astex Pharmaceuticals to Announce 2012 First Quarter Financial Results on April 30, 2012

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2012-04-24 09:58:572016-12-01 16:42:18Astex Pharmaceuticals to Announce 2012 First Quarter Financial Results on April 30, 2012

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: Astex Pharmaceuticals to Present AT26893, a Novel Targeted Approach to the Treatment of HCV at EASL Link to: Astex Pharmaceuticals to Present AT26893, a Novel Targeted Approach to the Treatment of HCV at EASL Astex Pharmaceuticals to Present AT26893, a Novel Targeted Approach to the Treatment... Link to: 2012 AACR: Scale up & development of a process for a low volume subcutaneous formulation of SGI-110 Link to: 2012 AACR: Scale up & development of a process for a low volume subcutaneous formulation of SGI-110 2012 AACR: Scale up & development of a process for a low volume subcutaneous...
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok